Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A new competitor enters the exon 53 skipping niche, and might well take it over.
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.